Platinum-Resistant Recurrent Ovarian Cancer
MRKMerck & CoCatalyst overview
Research summary
This catalyst tracks a Approved quarterly sales for KEYTRUDA® plus chemotherapy +/- bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer . The expected timing is based on the latest available company guidance and may change.
KEYNOTE-B96/ENGOT-ov65 trial. 5/15/25- Trial Met Primary Endpoint of Progression-Free Survival (PFS). Also met secondary endpoint. 10/18/25- FDA accepted sBLA for priority review with PDUFA date of Feb. 20, 2026. 02/10/26:- FDA approved KEYTRUDA and KEYTRUDA QLEX with paclitaxel ± bevacizumab for PD-L1+ platinum-resistant ovarian carcinoma. 02/27/26:- Final KEYNOTE-B96 OS analysis showed significant OS benefit; ESGO 2026 presentation; EU CHMP positive opinion.
Verification
Confirm timing and program details against the company announcement or filing.